In the remaining 5 cases, the deposits were replaced by electron-lucent material, reflecting almost complete reabsorption of deposits as seen in stage IV IMN, although mixed patterns were found (Table 3)
In the remaining 5 cases, the deposits were replaced by electron-lucent material, reflecting almost complete reabsorption of deposits as seen in stage IV IMN, although mixed patterns were found (Table 3). == Physique 1. range) IgG4 staining score decreased from 3 (33) to 1 1 (02), whereas total numbers of slit diaphragms (0.27; range, 0.19 to 0.30versus0.86; range, 0.53 to 1 1.16 slits/m glomerular basement membrane) and ORM-10962 percentages of those with electron-dense diaphragm (55.2; range, 42.0 to 62.0versus78.5; range, 73.0 to 82.7 of all slits) significantly increased in parallel with amelioration of glomerular ultrastructural changes. Changes in slit frequency and albumin fractional clearance were negatively correlated (r = 0.79). Conclusions: In human IMN, treatment-induced NS remission is usually associated with restoration of sodium homeostasis and kidney hemodynamics, and regression of the glomerular changes underlying proteinuria. These effects are likely to translate into long-term renoprotection. Idiopathic membranous nephropathy (IMN), the most common cause of the nephrotic syndrome in whites, is an immune-mediated disease resulting from deposition of immunoglobulin G (IgG) and complement components around the subepithelial layer of the glomerular capillary wall (1). The production of nephritogenic immunoglobulins by B cells is one of the earliest actions in the sequence of pathogenic events underlying progressive renal dysfunction in IMN. So far, however, therapeutic approaches to IMN have mostly relied on steroids and immunosuppressant drugs, such as alkylating brokers, calcineurin inhibitors, and mycophenolate mofetil, which are not fully specific and carry the risk of severe toxic effects, without appreciably affecting patient and kidney survival (2). This may explain why, over the past 30 yr, the outcome of IMN has not substantially improved. Up to 40% of patients still progress to end-stage renal failure despite treatment (3). Conceivably, treatments targeted to specific pathogenic mechanisms might limit disease activity more effectively and with less side effects than aspecific immunosuppression. Brokers that specifically interfere with B cells ideally represent the first step toward selective therapy (4). With this rationale, we first investigated the efficacy and safety profile of rituximab (Roche, Monza, Italy), a monoclonal antibody against the cell surface antigen CD20 of B cells (5), in 8 IMN patients with persistent nephrotic syndrome refractory to conservative treatment and without previous spontaneous or treatment-induced remissions (6,7). Treatment reduced urinary proteins by 60% and stabilized kidney function in all patients over 1-yr follow-up (6,7). These encouraging results, which still have to be confirmed in a randomized controlled clinical trial, stimulated studies on the use of rituximab for primary ORM-10962 glomerular diseases, and several reports subsequently confirmed and extended our initial findings (810). Following this preliminary experience, we treated (with rituximab) 50 consecutive patients with IMN and long-lasting nephrotic syndrome refractory to usual treatments. Ten of these patients achieved full and persistent reduction of 24 h proteinuria to less than 0.5 g. Here we evaluated: 1) whether normalization of urinary proteins corrected the functional abnormalities of the nephrotic syndrome and 2) whether this effect could be associated with regression of abnormal IgG deposition ORM-10962 and ultrastructural changes in repeat biopsies. Results of this analysis formed the basis of the present Mouse monoclonal to CD48.COB48 reacts with blast-1, a 45 kDa GPI linked cell surface molecule. CD48 is expressed on peripheral blood lymphocytes, monocytes, or macrophages, but not on granulocytes and platelets nor on non-hematopoietic cells. CD48 binds to CD2 and plays a role as an accessory molecule in g/d T cell recognition and a/b T cell antigen recognition report. == Materials and Methods == == Patients and Study Design == From May 2001 to January 2007, we treated (with rituximab) 50 consecutive patients with biopsy-proven IMN and a creatinine clearance >20 ml/min per 1.73 ORM-10962 m2who had no previous spontaneous or treatment-induced remissions. Patients had persistent urinary protein excretion rate greater than 3.5 g/24 h despite continued angiotensin-converting enzyme (ACE) inhibitor therapy (ramipril 5 to 10 mg/d) for at least 6 mo. All patients were on a standard low sodium (2 to 3 3 g/d Na+Cl) and controlled protein (0.8 g/kg body weight /d).